Orexigen is now facing the repercussions of Takeda Pharmaceuticals' decision to terminate their partnership for obesity drug Contrave.
It came to light on April 13 that the biotech has now ended a second cardiovascular outcomes (CVOT) study, failing once again to fulfill its post-marketing requirements put in place...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?